Consun Pharma Repurchases 50,000 Shares; Treasury Stock Rises to 3.75 Million

Bulletin Express09-17

Consun Pharmaceutical Group Limited (Consun Pharma) reported that on 17 September 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange, transferring them to treasury stock. The transaction was executed within a price range of HKD 13.09–13.15 per share, representing a volume-weighted average purchase cost of HKD 13.11 per share and an aggregate consideration of HKD 0.66 million.

Following the buyback: • Issued shares (excluding treasury stock) declined to 837.84 million from 837.89 million, a reduction of 0.006%. • Treasury shares increased to 3.75 million. • Total issued shares remained unchanged at 841.59 million, as the repurchased shares were retained in treasury rather than cancelled.

The repurchase was conducted under the general mandate approved on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. Cumulative repurchases under this mandate now total 3.41 million shares, equivalent to 4.05% of the issued share capital outstanding on the mandate date. In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124699438?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124699438","market":"hk","top_or_hot":-1,"title":"Consun Pharma Repurchases 50,000 Shares; Treasury Stock Rises to 3.75 Million","media":"Bulletin Express","content":"<p>Consun Pharmaceutical Group Limited (Consun Pharma) reported that on 17 September 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange, transferring them to treasury stock. The transaction was executed within a price range of HKD 13.09–13.15 per share, representing a volume-weighted average purchase cost of HKD 13.11 per share and an aggregate consideration of HKD 0.66 million.</p>\n<p>Following the buyback:\n• Issued shares (excluding treasury stock) declined to 837.84 million from 837.89 million, a reduction of 0.006%.  \n• Treasury shares increased to 3.75 million.  \n• Total issued shares remained unchanged at 841.59 million, as the repurchased shares were retained in treasury rather than cancelled.</p>\n<p>The repurchase was conducted under the general mandate approved on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. Cumulative repurchases under this mandate now total 3.41 million shares, equivalent to 4.05% of the issued share capital outstanding on the mandate date. In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consun Pharma Repurchases 50,000 Shares; Treasury Stock Rises to 3.75 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsun Pharma Repurchases 50,000 Shares; Treasury Stock Rises to 3.75 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-17 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Consun Pharmaceutical Group Limited (Consun Pharma) reported that on 17 September 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange, transferring them to treasury stock. The transaction was executed within a price range of HKD 13.09–13.15 per share, representing a volume-weighted average purchase cost of HKD 13.11 per share and an aggregate consideration of HKD 0.66 million.</p>\n<p>Following the buyback:\n• Issued shares (excluding treasury stock) declined to 837.84 million from 837.89 million, a reduction of 0.006%.  \n• Treasury shares increased to 3.75 million.  \n• Total issued shares remained unchanged at 841.59 million, as the repurchased shares were retained in treasury rather than cancelled.</p>\n<p>The repurchase was conducted under the general mandate approved on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. Cumulative repurchases under this mandate now total 3.41 million shares, equivalent to 4.05% of the issued share capital outstanding on the mandate date. In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01681","symbol_name":"康臣药业","start_time":0,"source_url":"","article_id":"1124699438","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124699438","pubTimestamp":1789641719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Consun Pharmaceutical Group Limited (Consun Pharma) reported that on 17 September 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange, transferring them to treasury stock. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01681":"康臣药业"},"translate_title":"康盛制药回购50,000股股票；美国库存增至375万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01681":1},"content_text":"Consun Pharmaceutical Group Limited (Consun Pharma) reported that on 17 September 2026 it repurchased 50,000 ordinary shares on the Hong Kong Stock Exchange, transferring them to treasury stock. The transaction was executed within a price range of HKD 13.09–13.15 per share, representing a volume-weighted average purchase cost of HKD 13.11 per share and an aggregate consideration of HKD 0.66 million.\nFollowing the buyback:\n• Issued shares (excluding treasury stock) declined to 837.84 million from 837.89 million, a reduction of 0.006%.  \n• Treasury shares increased to 3.75 million.  \n• Total issued shares remained unchanged at 841.59 million, as the repurchased shares were retained in treasury rather than cancelled.\nThe repurchase was conducted under the general mandate approved on 26 May 2026, which authorises the company to buy back up to 84.12 million shares. Cumulative repurchases under this mandate now total 3.41 million shares, equivalent to 4.05% of the issued share capital outstanding on the mandate date. In accordance with Hong Kong listing rules, Consun Pharma is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124699438","isCrawlerRequest":true}